Phaseline

Companies › DBV Technologies

DBV Technologies: clinical trials, targets and expected readouts

1 active drug program in 3 registered trials: 3 Phase 3; Other; next expected readout Nov 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Viaskin Peanut 250µg (DBV712)
Epicutaneous immunotherapy (EPIT) for peanut allergy
–Phase 3Peanut Allergy; Allergy; Allergy, PeanutNov 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT03013517Viaskin Peanut 250µg (DBV712)Phase 3Peanut AllergyOtherNov 2019
NCT07003919Viaskin Peanut 250µg (DBV712)Phase 3AllergyOtherNov 2026
NCT05741476Viaskin Peanut 250µg (DBV712)Phase 3Allergy, PeanutOtherOct 2029

Specialist investors

Held by 2 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

CUTISS Gameto Merz Aesthetics Merz North America CellTherX

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.